Biotech entity
pharma is the sole category represented across all 1 tracked stories. Substance Abuse and Mental Health Services Administration (SAMHSA) is most often covered alongside Opioid treatment providers, which appears in 1 of these 1 story. Each carries 2 original sources on average.
Last mentioned: Aug 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Substance Abuse and Mental Health Services Administration (SAMHSA) is most often covered alongside Opioid treatment providers, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Substance Abuse and Mental Health Services Administration (SAMHSA), all published on August 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Substance Abuse and Mental Health Services Administration (SAMHSA). Shared-story counts are live from our verified record — not editorial picks.
HHS announced $281M in mental health and addiction grants, with $68.2M dedicated to medication-assisted treatment (MAT) for opioid use disorder, opening demand opportunities for pharma companies and biotech startups in the addiction space.
Source: hawaiitribune-herald.com · slguardian.org
Substance Abuse and Mental Health Services Administration (SAMHSA) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
